Navigation Links
Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
Date:10/22/2008

Phase 3 sleep-lab study demonstrated that low dose sublingual

Intermezzo(R), used at the time of a middle of the night awakening,

significantly shortened time to return to sleep vs. placebo

PT. RICHMOND, Calif., Oct. 22 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that a Phase 3 study evaluating the safety and efficacy of its lead product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge), has been published in the September 2008 issue of SLEEP, a publication of the Associated Professional Sleep Societies. Intermezzo(R) is a low dose, buffered, sublingual formulation of zolpidem intended to be the first prescription sleep aid to be indicated for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.

On September 30, 2008, Transcept submitted a New Drug Application for Intermezzo(R) to the U.S. Food and Drug Administration. On August 29, 2008, Transcept and Novacea, Inc. (Nasdaq: NOVC) entered into a definitive merger agreement under which, if completed, Novacea will merge with Transcept. Assuming a close near the end of 2008, the combined company is expected to have an estimated cash balance of $88 to $92 million.

Thomas Roth, Ph.D., Director of Research, Chief of Sleep Medicine for the Henry Ford Hospital Sleep Disorders and Research Center, was the principal author and investigator for the randomized, double-blind, placebo-controlled, 3-way cross-over study of the safety and efficacy of Intermezzo(R) at doses of 1.75 mg and 3.5 mg compared to placebo. The study evaluated 82 adults at five sleep laboratories with a diagnosis of DSM-IV primary in
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... December 18, 2014 Reports from ... United States suffer from one or more chronic health ... cancer. Medication can address some of these diseases, but ... that many sufferers face. While implanted nerve stimulation devices ... the whole nerve, which can induce side effects. ...
(Date:12/19/2014)... (PRWEB) December 18, 2014 With only ... time special on Sartorius Biohit products . The ... mLINE pipettes, Picus Electronic Pipette Trade-in Program, and free ... and Safety officers around the world. They are ideal ... Other features include:, ,     Full volume range ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced the results of ... "This was a transformational year in Relmada,s history ... for our company," said Sergio Traversa , chief ... have executed on key financial, human resource and clinical ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Achim Noack ... administration for Stoller Group. In this position, Noack will ... on administrative matters, develop marketing strategy and supervise global ... , “Achim has tremendous knowledge and experience in ... Stoller Group. “His experience and innovative thinking will be ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... in a lab dish to the steroid DHEA, exhibit a ... play a role in helping the brain produce new cells, ... online editions of the Proceedings of the National Academy of ... of scientists at the University of Wisconsin-Madison, provides some of ...
... , a data quality solutions provider, announced today ... Information Quality Suite to work with Oracle Warehouse ... intelligence integration design tool that manages data lifecycles. ... intelligence application and customize the way data quality ...
... Inc. announced Tuesday that its genetic analysis ... chromosomal analysis, opening a new market to the ... extension of the Invader technology, Madison-based Third Wave ... (ASRs) for prenatal chromosomal analysis to the University ...
Cached Biology Technology:DHEA Boosts Growth Rate of Human Neural Stem Cells 2DHEA Boosts Growth Rate of Human Neural Stem Cells 3
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... M.D., director of the National Institute of Allergy and Infectious ... been awarded the 2007 Mary Woodard Lasker Award for Public ... health programs, in AIDS and biodefense. The award will be ... New York City. , Dr. Fauci is honored for his ...
... in conjunction with the National Evolutionary Synthesis Center, will ... 1, 2007, at the Hyatt Regency Hotel in Atlanta, ... and Populations, is part of the 2007 Professional Development ... The aim of the symposium is ...
... National Institutes of Health has awarded one of 12 ... a team based at the University of Chicago Medical ... 2006, form the core of an NIH effort to ... "transform how clinical and translational research is conducted," ultimately ...
Cached Biology News:Anthony S. Fauci awarded Lasker Award for Public Service 2Anthony S. Fauci awarded Lasker Award for Public Service 3Anthony S. Fauci awarded Lasker Award for Public Service 4AIBS to cohost symposium on evolution, disease and human health 2AIBS to cohost symposium on evolution, disease and human health 3AIBS to cohost symposium on evolution, disease and human health 4NIH awards nearly $23M to University of Chicago for translational research 2NIH awards nearly $23M to University of Chicago for translational research 3NIH awards nearly $23M to University of Chicago for translational research 4
... The MiniOpticon 2-color real-time PCR detection system holds ... microplate. An array of 48 LEDs independently excites ... pair of filtered photodiodes detects emitted light (523-543 ... on a MJ Mini cycler, whose Peltier heat ...
... mobility shift assay (EMSA) is a powerful ... to as gel shift or gel retardation, ... that when subjected to electrophoresis, free DNA ... The Pierce LightShift Chemiluminescent EMSA Kit is ...
... The Cell Lab Quantas unique ... provides unsurpassed population resolution capabilities and ... has multiple excitation wavelengths, including UV, ... variety of multi-color applications typically only ...
... a novel procedure for the uniform amplification ... genome DNA from small samples. This method ... and highly reproducible amplification and labeling procedure ... REPLI-g Mini Kit module (QIAGEN) and a ...
Biology Products: